With notable implications in pharmaceutical research, particularly as angiotensin-converting enzyme (ACE) and aminopeptidase inhibitors, microginins offer a promising avenue for the development of innovative therapeutic modalities in diverse medical fields, ranging from treatments for cardiovascular disorders to oncological interventions. This evidence concerns the gene ACE and cardiovascular disorder.